Compare GRC & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | OLMA |
|---|---|---|
| Founded | 1933 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 1994 | 2020 |
| Metric | GRC | OLMA |
|---|---|---|
| Price | $61.25 | $13.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $44.89 |
| AVG Volume (30 Days) | 124.9K | ★ 1.6M |
| Earning Date | 04-23-2026 | 03-16-2026 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 32.03 | 15.00 |
| EPS | ★ 2.02 | N/A |
| Revenue | ★ $682,389,000.00 | N/A |
| Revenue This Year | $6.62 | N/A |
| Revenue Next Year | $4.66 | $347.47 |
| P/E Ratio | $31.00 | ★ N/A |
| Revenue Growth | ★ 3.44 | N/A |
| 52 Week Low | $30.87 | $2.86 |
| 52 Week High | $68.02 | $36.26 |
| Indicator | GRC | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 48.96 | 27.43 |
| Support Level | $56.98 | $4.15 |
| Resistance Level | $67.61 | $27.38 |
| Average True Range (ATR) | 2.36 | 1.07 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 51.50 | 16.67 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of revenue from the United States.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.